REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II.

I. Chau; A.F.C. Okines; D.G. de Castro; C. Saffery; Y. Barbachano; A. Wotherspoon; L. Puckey; S.H. Wilson; F.Y. Coxon; G.W. Middleton; D.R. Ferry; T.D.L. Crosby; S. Madhusudan; J. Wadsley; J.S. Waters; M. Hall; D. Swinson; A. Robinson; D. Smith; D. Cunningham; U.K.N.C.R.I.U. Gastro

REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II.

I. Chau, A.F.C. Okines, D.G. de Castro, C. Saffery, Y. Barbachano, A. Wotherspoon, L. Puckey, S.H. Wilson, F.Y. Coxon, G.W. Middleton, D.R. Ferry, T.D.L. Crosby, S. Madhusudan, J. Wadsley, J.S. Waters, M. Hall, D. Swinson, A. Robinson, D. Smith, D. CunninghamU.K.N.C.R.I.U. Gastro

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Journal of Clinical Oncology
Volume	29
Issue number	15
Publication status	Published - 20 May 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208880300540&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9

Cite this

Chau, I., Okines, A. F. C., de Castro, D. G., Saffery, C., Barbachano, Y., Wotherspoon, A., Puckey, L., Wilson, S. H., Coxon, F. Y., Middleton, G. W., Ferry, D. R., Crosby, T. D. L., Madhusudan, S., Wadsley, J., Waters, J. S., Hall, M., Swinson, D., Robinson, A., Smith, D., ... Gastro, U. K. N. C. R. I. U. (2011). REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II. Journal of Clinical Oncology, 29(15). http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208880300540&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9

@article{2c7f3049187a43908dee04d062ca7ae0,

title = "REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II.",

author = "I. Chau and A.F.C. Okines and \{de Castro\}, D.G. and C. Saffery and Y. Barbachano and A. Wotherspoon and L. Puckey and S.H. Wilson and F.Y. Coxon and G.W. Middleton and D.R. Ferry and T.D.L. Crosby and S. Madhusudan and J. Wadsley and J.S. Waters and M. Hall and D. Swinson and A. Robinson and D. Smith and D. Cunningham and U.K.N.C.R.I.U. Gastro",

year = "2011",

month = may,

day = "20",

language = "English",

volume = "29",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "15",

}

Chau, I, Okines, AFC, de Castro, DG, Saffery, C, Barbachano, Y, Wotherspoon, A, Puckey, L, Wilson, SH, Coxon, FY, Middleton, GW, Ferry, DR, Crosby, TDL, Madhusudan, S, Wadsley, J, Waters, JS, Hall, M, Swinson, D, Robinson, A, Smith, D, Cunningham, D & Gastro, UKNCRIU 2011, 'REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II.', Journal of Clinical Oncology, vol. 29, no. 15. <http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208880300540&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9>

REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II. / Chau, I.; Okines, A.F.C.; de Castro, D.G. et al.
In: Journal of Clinical Oncology, Vol. 29, No. 15, 20.05.2011.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II.

AU - Chau, I.

AU - Okines, A.F.C.

AU - de Castro, D.G.

AU - Saffery, C.

AU - Barbachano, Y.

AU - Wotherspoon, A.

AU - Puckey, L.

AU - Wilson, S.H.

AU - Coxon, F.Y.

AU - Middleton, G.W.

AU - Ferry, D.R.

AU - Crosby, T.D.L.

AU - Madhusudan, S.

AU - Wadsley, J.

AU - Waters, J.S.

AU - Hall, M.

AU - Swinson, D.

AU - Robinson, A.

AU - Smith, D.

AU - Cunningham, D.

AU - Gastro, U.K.N.C.R.I.U.

PY - 2011/5/20

Y1 - 2011/5/20

M3 - Article

SN - 0732-183X

VL - 29

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

ER -

Chau I, Okines AFC, de Castro DG, Saffery C, Barbachano Y, Wotherspoon A et al. REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II. Journal of Clinical Oncology. 2011 May 20;29(15).